Century Therapeutics, Inc. IPSC
We take great care to ensure that the data presented and summarized in this overview for Century Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IPSC
View all-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$5.63 Million1.66% of portfolio
-
Vr Adviser, LLC New York, NY5.39MShares$5.6 Million0.95% of portfolio
-
Boxer Capital, LLC San Diego, CA3.9MShares$4.06 Million0.35% of portfolio
-
Casdin Capital, LLC New York, NY3.21MShares$3.34 Million0.43% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$3.01 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.48MShares$2.57 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.27MShares$2.36 Million0.0% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA1.7MShares$1.77 Million0.75% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.32MShares$1.38 Million0.0% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X01.21MShares$1.26 Million2.57% of portfolio
Latest Institutional Activity in IPSC
Top Purchases
Top Sells
About IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Insider Transactions at IPSC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2024
|
Brent Pfeiffenberger President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
243,447
-16.55%
|
$243,447
$1.44 P/Share
|
|
Nov 04
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
1,033
-0.76%
|
$1,033
$1.23 P/Share
|
|
Nov 04
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
283
-0.09%
|
$283
$1.23 P/Share
|
|
Nov 01
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
16,611
-4.97%
|
$16,611
$1.26 P/Share
|
|
Oct 14
2024
|
Morgan Conn Chief Finanical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,148
+50.0%
|
-
|
|
Oct 01
2024
|
Chad Cowan Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,376
+26.08%
|
-
|
|
Sep 12
2024
|
Daphne Quimi Director |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$5,000
$1.53 P/Share
|
|
Aug 05
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
289
-0.09%
|
$289
$1.83 P/Share
|
|
Aug 05
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
1,073
-0.78%
|
$1,073
$1.83 P/Share
|
|
Jul 26
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
586
-0.21%
|
$1,172
$2.5 P/Share
|
|
Jul 24
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
1,600
-0.58%
|
$3,200
$2.52 P/Share
|
|
Jul 23
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
200
-0.07%
|
$400
$2.5 P/Share
|
|
Jun 20
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.77%
|
$10,000
$2.84 P/Share
|
|
Jun 07
2024
|
Douglas Carr SVP Finance & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
17,007
+4.84%
|
-
|
|
Jun 05
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.74%
|
$15,000
$3.0 P/Share
|
|
May 20
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.71%
|
$15,000
$3.0 P/Share
|
|
May 06
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.68%
|
$15,000
$3.12 P/Share
|
|
May 03
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
913
-0.66%
|
$2,739
$3.11 P/Share
|
|
May 03
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
257
-0.08%
|
$771
$3.11 P/Share
|
|
Apr 22
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.65%
|
$15,000
$3.1 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 5K shares |
|---|---|
| Grant, award, or other acquisition | 255K shares |
| Exercise of conversion of derivative security | 54K shares |
| Open market or private sale | 90.3K shares |
|---|---|
| Payment of exercise price or tax liability | 260K shares |